Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Plans New Incentives As it Tackles Antibiotic Resistance Issues

Executive Summary

Japan has kick-started discussions on incentives for R&D and continued marketing of antibiotics as part of broader measures to counter resistance issues and industry reluctance to develop new drugs. The country plans to open applications for a pilot project in the summer after initial discussions on specific targets.

You may also be interested in...



Panel Tells Canadian Govt A Subscription-Style Pull Incentive Is Needed To Tackle AMR

An expert panel formed by the Council of Canadian Academies says drug developers that provide “novel, valuable antibiotic solutions” should be rewarded with a “fair and reasonable guaranteed revenue” for their drugs.

Japan Lists Eight Infectious Diseases For Focused Vaccine Development

The list including eight types of diseases such as flu and coronavirus infection, smallpox will be sent to SCARDA to determine which domestic vaccine development projects by pharmaceutical firms are to be funded. Some participants at the Ministry of Health, Labour and Welfare’s discussion insisted on continuous monitoring.

England: Shionogi And Pfizer Ink ‘World First’ Payment Model Deal For Antibiotics

Shionogi and Pfizer have formally agreed to a scheme that offers companies a new and sustainable payment model for innovating in antibiotics.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS148007

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel